Wolfgang Bertold has over 40 years of experience in biologics development and manufacturing. He has been an innovating pioneer in biotechnology development and manufacturing and later served as a Supervisory Board Member for multiple biotech companies. He started his carrier with Boehringer-Ingelheim, Germany, in 1979 where he held multiple positions with increasing responsibilities in research and development. In 1995, Wolf joined Hoffmann-La Roche in Nutley, New Jersey, as the Head of Biotech Production and Development where he was instrumental in the first regulatory approval of a PEGylated interferon (Pegasys). Later he joined IDEC Pharmaceuticals and Biogen IDEC in San Diego, CA and Boston, MA as the Senior Vice President of Development and Operations and then was the Chief Technology Officer at Biogen in Zug, Switzerland. In his distinguished carrier, Wolf was instrumental in the CMC development and manufacturing of some of the very first FDA approved biologics, such as tPA and monoclonal antibodies, and later in extended half-life biologics, fusion proteins, coagulation factors, and biosimilars. Through his visionary leadership, Wolf was also responsible for the development, construction, and operations of multiple large-scale, biologic manufacturing facilities in Europe and the USA.
Wolf earned his PhD in biochemistry from the University of London, UK, after undergraduate studies in medicine and biochemistry from the University of Hamburg and Tübingen, Germany.
At Cilatus, Wolf enjoys contributing as the Biologics technical development and manufacturing expert and helping clients in tailoring smart, customized CMC development and manufacturing strategies.
